Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).

Jianming Xu, Yanqi Wang, Qingxia Fan et al.|Journal of Clinical Oncology|2020

Cited by 24